Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. - Wikidata - awgldk - TriplyDB

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

http://www.wikidata.org/entity/Q33973552

about

Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparin for prevention of venous thromboembolism following total hip or knee replacement or hip repair Ximelagatran: direct thrombin inhibitor New anticoagulants for the prevention and treatment of venous thromboembolism Anticoagulation for non-valvular atrial aibrillation - towards a new beginning with ximelagatran Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation Therapeutic approaches in arterial thrombosis Will oral antithrombin agents replace warfarin?Anti-inflammatory and immunosuppressive drugs and reproduction CT pulmonary angiography after total joint arthroplasty: overdiagnosis and iatrogenic harm?Ximelagatran: a new type of oral anticoagulant.Current issues in anticoagulation.Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.Lessons from ximelagatran: issues for future studies evaluating new oral direct thrombin inhibitors for venous thromboembolism prophylaxis in orthopedic surgery.Ximelagatran (Exanta): alternative to warfarin?Diet as prophylaxis and treatment for venous thromboembolism?Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin.Ximelagatran: light at the end of the tunnel or the next tunnel?Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.Challenges in the prevention of venous thromboembolism in the elderly.Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management.Ximelagatran: an oral direct thrombin inhibitor.The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism.An automated database case definition for serious bleeding related to oral anticoagulant use.Current concepts for the prevention of venous thromboembolism.New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin Ximelagatran in orthopaedic surgery.The pharmacogenetics of coumarin therapy.Ximelagatran for stroke prevention in atrial fibrillation.The influence of tourniquet use and operative time on the incidence of deep vein thrombosis in total knee arthroplasty A preliminary assessment of the critical differences between novel oral anticoagulants currently in development.Update on the diagnosis and management of pulmonary embolism.Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials.The status of new anticoagulants.Biomarkers and surrogate endpoints in clinical trials Ximelagatran versus warfarin for prophylaxis of venous thromboembolism in major orthopedic surgery: systematic review of randomized controlled trials.Investigational treatments of venous thromboembolism.

P2860

Q21090146-27CE1EA5-EEBF-47D9-8CBA-AB7DBCFF6024 Q24235993-3F71FD44-0990-4EFF-84F3-DEACD17B1CC4 Q24244149-D532C20E-BFD0-4122-8D9F-F036ADEEC967 Q24681333-65CE7A69-823B-4B4E-9D94-E2018C0F3957 Q24681351-611B9B6E-DD00-4796-A4FB-3CD61D98B9A8 Q24807132-A9A09E27-BF0A-42A0-8F7B-868C2EA2C8CC Q28176666-0F912E6C-9157-40BB-B209-95E499A535C9 Q28187576-2E1DB9D8-49EC-4E59-B9B9-03A7792FA656 Q28208671-71D3559C-1A70-4659-A003-C0F358AF6697 Q28218219-812B6052-75B3-4E96-8742-1C8B0F6EF4B6 Q30410953-ECDC0888-4007-46E4-A8DD-2119544715AF Q33226419-5C89C0B6-9BB5-4ABA-86FA-40B6281760DA Q33365707-6ABEAC50-0B26-4BC6-8840-443D8DF4844C Q33381801-6E38659C-BB59-4811-9EC7-B1D692B26A93 Q33386637-D65847F4-BFA9-4897-93DA-926D647FD34F Q33945088-FDFDFDDF-F81C-43B6-810A-C9A1EC5F79BF Q34078303-02C299A2-4666-49CD-8AD1-E4A37D04D8D7 Q35218128-4607C762-F28D-44C7-A494-6C1BFE85B98D Q35777336-D80C93CF-8DA5-4F27-AE71-DF7C70CB72AF Q35779232-F2ED04F9-036E-44B4-AE52-6306939460BB Q35843153-4BC92389-D31E-4D91-99CF-FDA9A00928D8 Q35843864-25B99617-A93C-40DB-A645-A74C6E748505 Q35860195-B3EFC4BE-AE81-4D77-8815-3C78B0BE86C2 Q35878355-3BB96936-A645-4EA5-A54A-1BDD4C0FA4F2 Q35895188-2240F7BD-5DA8-4241-8F6D-B8131D503C5D Q35996019-86FB7999-11B1-4438-A5EC-4B636FBF706A Q36002461-3E3D6365-9922-4158-B422-31B0D43497BE Q36034723-1BAD6C02-F7A9-4FFC-B5C9-3941533177E5 Q36042279-0EA47A57-8502-4903-853F-29DB36BF6C59 Q36090077-7A0D6952-9018-4CEF-9A82-576488AAEB24 Q36192806-16862751-11FF-47B0-9D06-AAE540E108E4 Q36216784-E88EDC12-5659-464A-8B17-6D14A7D7AE6E Q36222993-A75BBC3F-1222-440C-B4E3-773213301472 Q36229356-DFEB4CA5-4714-498C-AD55-61FBC635AB38 Q36286443-97E8FCCA-4127-4C9F-83D2-E55DF66106AC Q36370296-66102B7C-2B41-4BD8-82F8-8A51D8A9137D Q36520745-F95C3C1A-3BAE-4432-B1BD-533238B06E3C Q36552129-32DD5EB9-3089-45F8-AEF9-5C97A985474D Q36745430-1191846D-7F0D-4FF4-AD34-7484345D516E Q36764001-04812D15-9921-4C04-AE53-67CBAC31DA1D

P2860

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

http://www.wikidata.org/entity/Q33973552

description

2003 nî lūn-bûn

@nan

2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Comparison of ximelagatran wit ...... after total knee replacement.

@ast

Comparison of ximelagatran wit ...... after total knee replacement.

@en

type

label

Comparison of ximelagatran wit ...... after total knee replacement.

@ast

Comparison of ximelagatran wit ...... after total knee replacement.

@en

prefLabel

Comparison of ximelagatran wit ...... after total knee replacement.

@ast

Comparison of ximelagatran wit ...... after total knee replacement.

@en

P1433

Q33973552-C2198C3F-693E-41DD-B31B-F9F09FFBC240

P1476

Q33973552-906571EC-9AE3-471D-A6DF-409AB2BBEB41

P2093

Q33973552-094DB6BA-1EBE-465F-A421-55C91C8E2852

Q33973552-0B09A50A-B123-40B7-9D38-ADB28F37C8FB

Q33973552-3D88560D-70A7-4A37-AE63-6C757BFEB839

Q33973552-42346021-F28A-4826-A945-83B3C0F76FD7

Q33973552-5350A138-73BC-4A29-8183-D28FFCA6D3B4

Q33973552-82186D52-80DF-4F58-AE7F-4D8964D8EC28

Q33973552-A9DC9B99-BC73-4838-9EBB-89F5A14949E9

Q33973552-B538E396-17AE-4DA4-8049-950E7C092DBE

Q33973552-BF1305AF-A0C6-4D9B-B913-B68127C26A88

Q33973552-C44FB408-3782-4077-8537-B12E1E936304

P304

Q33973552-295CCFF6-0FC0-4619-8DEF-8CCFC3418D86

P31

Q33973552-66116B14-4854-4A6B-9D75-6C75D32AD0F1

P356

Q33973552-F9D76723-D74C-4E71-8DA9-368283481DBE

P407

Q33973552-1BD9DF51-7C02-417B-B7A2-E84023D735B3

P433

Q33973552-C1129128-05AD-4A2E-A43F-07B3A87578E1

P478

Q33973552-7DF6ADE8-4012-4FF4-A7E9-7DC9355ADCBA

P50

Q33973552-102F1E24-9225-4362-9010-8DFF9C7A10FD

P577

Q33973552-A9AA6AB5-61B3-411F-BCC4-513950F4BC53

P698

Q33973552-095264A9-60E5-4DFA-8DFE-0C3DE81AEA8A

P356

P1433

The New England Journal of Medicine

P1476

Comparison of ximelagatran wit ...... m after total knee replacement

@en

P2093

Anne W Roth

http://www.w3.org/2001/XMLSchema#string

Charles W Francis

http://www.w3.org/2001/XMLSchema#string

Clifford W Colwell

http://www.w3.org/2001/XMLSchema#string

EXULT A Study Group

http://www.w3.org/2001/XMLSchema#string

Gary R Peters

http://www.w3.org/2001/XMLSchema#string

Guy Paiement

http://www.w3.org/2001/XMLSchema#string

Jay R Lieberman

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Ginsberg

http://www.w3.org/2001/XMLSchema#string

Jennifer McElhattan

http://www.w3.org/2001/XMLSchema#string

Philip C Comp

http://www.w3.org/2001/XMLSchema#string

P304

1703-1712

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA035162

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

349

http://www.w3.org/2001/XMLSchema#string

P50

Scott D Berkowitz

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14585938

http://www.w3.org/2001/XMLSchema#string